Hemodialysis (HD) vascular access dysfunction is currently a huge clinical problem for which there are no effective therapies. There are, however, a number of promising technologies that are currently at the experimental or clinical trial stage. We believe that the application of these novel technologies in combination with better clinical protocols for vascular access care could significantly reduce the current problems associated with HD vascular access.
FalkA.Maintenance and salvage of arteriovenous fistulas. J Vasc Interv Radiol2006; 17: 807–13.
5.
DemberL.M., BeckG.J., AllonM.Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA2008; 299: 2164–71.
6.
PatelS.T., HughesJ., MillsJ.L.Sr. Failure of arteriovenous fistula maturation: an unintended consequence of exceeding dialysis outcome quality Initiative guidelines for hemodialysis access. J Vasc Surg2003; 38: 439–45; discussion 45.
7.
Roy-ChaudhuryP., KellyB.S., MelhemM.Vascular access in hemodialysis: issues, management, and emerging concepts. Cardiol Clin2005; 23: 249–73.
8.
DixonB.S.Effect of extended release dipyridamole plus aspirin on hemodialysis arteriovenous graft patency. In: National Kidney Foundation Spring Clinical Meeting. Dallas; 2008.
9.
SchwabS.J., HarringtonJ.T., SinghA.Vascular access for hemodialysis. Kidney Int1999; 55: 2078–90.
ButterlyD.W., SchwabS.J.Catheter access for hemodialysis: an overview. Semin Dial2001; 14: 411–5.
12.
AllonM., DaugirdasJ., DepnerT.A., GreeneT., OrntD., SchwabS.J.Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis2006; 47: 469–77.
13.
DhingraR.K., YoungE.W., Hulbert-ShearonT.E., LeaveyS.F., PortF.K.Type of vascular access and mortality in US hemodialysis patients. Kidney Int2001; 60: 1443–51.
14.
USRDS.USRDS 2008 Annual Data Report: atlas of end-stage renal disease in the United States.National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008.
15.
BeathardG.A., ArnoldP., JacksonJ., LitchfieldT.Aggressive treatment of early fistula failure. Kidney Int2003; 64: 1487–94.
16.
Roy-ChaudhuryP., ArendL., ZhangJ.Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis2007; 50: 782–90.
17.
Roy-ChaudhuryP., SukhatmeV.P., CheungA.K.Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol2006; 17: 1112–27.
18.
LawsonJ., ConteM., GlickmanM.Safety of vascugel treatment after the creation of arteriovenous access. J Am Soc Nephrol2008; 19: 251A.
19.
BurkeS., FrananoF., LaRochelleA., MendenhallH.Local application of recombinant human type i pancreatic elastase (PRT-201) to an arteriovenous fistula (AVF) increases AVF blood flow in a rabbit model. J Am Soc Nephrol2008; 19: 252A.
20.
Roy-ChaudhuryP., WangY., KrishnamoorthyM., DakinA.Optiflow: a novel anastomotic conduit for reducing AV fistula dysfunction. J Am Soc Nephrol2008; 19: 253A.
SwedbergS.H., BrownB.G., SigleyR., WightT.N., GordonD., NichollsS.C.Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. Circulation1989; 80: 1726–36.
23.
KellyB., MelhemM., ZhangJ.Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. Nephrol Dial Transplant2006; 21: 2425–31.
24.
KohlerT.R., ToleikisP., GravettD.M., AvelarR.L.Inhibition of neointimal hyperplasia in a sheep model of dialysis access failure with the bioabsorbable vascular wrap pacliteaxel eluting mesh. J Vasc Surg2007; 45: 1029–38.
25.
Roy-ChaudhuryP., KohlerTed, AvelarRui. Rationale, design, methods and statistical aspects of a randomized, multicenter, clinical study to assess the effectiveness of maintaining patency and the safety of the vascular wraptrade; paclitaxel-eluting mesh implanted with a Lifespan® ePTFE vascular graft for hemodialysis vascular access. J Am Soc Nephrol2007; 18: 469A.
26.
LeeB.H., LeeJ.E., LeeK.W.Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis. Nephrol Dial Transplant2007; 22: 2800–4.
27.
LeeB.H., NamH.Y., KwonT.Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis. Nephrol Dial Transplant2006; 21: 2432–8.
28.
RotmansJ.I., PattynamaP.M., VerhagenH.J.Sirolimus-eluting stents to abolish intimal hyperplasia and improve flow in porcine arteriovenous grafts: a 4-week follow-up study. Circulation2005; 111: 1537–42.
29.
PaulsonW., KipshidzeN., KipianiK., DeVitaM.V., ShenoyS., IyerS.Safety and efficacy of locally eluted sirolimus for prolonging AV graft patency (PTFE graft plus Coll-R)-first in man experience. J Am Soc Nephrol2008; 19: 252A.
KellyB.S., NarayanaA., HeffelfingerS.C.External beam radiation attenuates venous neointimal hyperplasia in a pig model of arteriovenous polytetrafluoroethylene (PTFE) graft stenosis. Int J Radiat Oncol Biol Phys2002; 54: 263–9.
32.
MisraS., BonanR., PfledererT., Roy-ChaudhuryP.BRAVO I: a pilot study of vascular brachytherapy in polytetrafluoroethylene dialysis access grafts. Kidney Int2006; 70: 2006–13.
33.
TaylorC., CahillJ., GerrishM., LittleJ.A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients. J Ren Care2008; 34: 116–20.
34.
TaklaT.A., ZelenitskyS.A., VercaigneL.M.Effectiveness of a 30% ethanol/4% trisodium citrate locking solution in preventing biofilm formation by organisms causing haemodialysis catheter-related infections. J Antimicrob Chemother2008; 62: 1024–6.
35.
OnderA.M., ChandarJ., BillingsA.A.Comparison of early versus late use of antibiotic locks in the treatment of catheter-related bacteremia. Clin J Am Soc Nephrol2008; 3: 1048–56.
36.
BleyerA.J.Use of antimicrobial catheter lock solutions to prevent catheter-related bacteremia. Clin J Am Soc Nephrol2007; 2: 1073–8.
37.
ManierskiC., BesarabA.Antimicrobial locks: putting the lock on catheter infections. Adv Chronic Kidney Dis2006; 13: 245–58.
38.
TobinE.J., BambauerR.Silver coating of dialysis catheters to reduce bacterial colonization and infection. Ther Apher Dial2003; 7: 504–9.
39.
ChatzinikolaouI., FinkelK., HannaH.Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study. Am J Med2003; 115: 352–7.
40.
BridgesC.New heparin coating reduces thrombosis and fibrin sheath formation in HD catheters. Nephrol News Issues2007; 21: 32, 4.
41.
FalkA.The role of surface coatings on central venous and hemodialysis catheters. Endovascular Today2008: 28–30.
